Search Results - "Clifton, Katherine"

Intermittent fasting in the prevention and treatment of cancer by Clifton, Katherine K., Ma, Cynthia X., Fontana, Luigi, Peterson, Lindsay L.

“…Chronic caloric restriction (CR) has powerful anticarcinogenic actions in both preclinical and clinical studies but may be difficult to sustain. As an…”
Get full text

Inadequate and delayed characterization of cutaneous reactions for US Food and Drug Administration–approved oncologic drugs from 2011–2020 leading to medication discontinuation by Yang, Jason J., So, Naomi, Maloney, Nolan J., Arzeno, Julia, Clifton, Katherine K., Bach, Daniel Q.

Get full text

Single-Institution Phase 1/2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial-Breast Irradiation for Hormone Sensitive Stage 0-I Breast Cancer by Kennedy, William R., Thomas, Maria A., Stanley, Jennifer A., Luo, Jingqin, Ochoa, Laura L., Clifton, Katherine K., Cyr, Amy E., Margenthaler, Julie A., DeWees, Todd A., Price, Alex, Kashani, Rojano, Green, Olga, Zoberi, Imran

“…We sought to evaluate the feasibility and tolerability of a novel accelerated partial breast irradiation regimen delivered in a single fraction…”
Get full text

Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer by Ademuyiwa, Foluso O., Chen, Ina, Luo, Jingqin, Rimawi, Mothaffar F., Hagemann, Ian S., Fisk, Bryan, Jeffers, Gejae, Skidmore, Zachary L., Basu, Anamika, Richters, Megan, Ma, Cynthia X., Weilbaecher, Katherine, Davis, Jennifer, Suresh, Rama, Peterson, Lindsay L., Bose, Ron, Bagegni, Nusayba, Rigden, Caron E., Frith, Ashley, Rearden, Timothy P., Hernandez-Aya, Leonel F., Roshal, Anna, Clifton, Katherine, Opyrchal, Mateusz, Akintola-Ogunremi, Olaronke, Lee, Byung Ha, Ferrando-Martinez, Sara, Church, Sarah E., Anurag, Meenakshi, Ellis, Matthew J., Gao, Feng, Gillanders, William, Griffith, Obi L., Griffith, Malachi

“…Purpose Patients with triple-negative breast cancer (TNBC) who do not achieve pathological complete response (pCR) following neoadjuvant chemotherapy have a…”
Get full text

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis by Gerratana, Lorenzo, Davis, Andrew A, Velimirovic, Marko, Clifton, Katherine, Hensing, Whitney L, Shah, Ami N, Dai, Charles S, Reduzzi, Carolina, D'Amico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A, Gradishar, William J, Behdad, Amir, Puglisi, Fabio, Ma, Cynthia X, Bardia, Aditya, Cristofanilli, Massimo

“…although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA mutations…”
Get full text

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab by Bagegni, Nusayba A, Davis, Andrew A, Clifton, Katherine K, Ademuyiwa, Foluso O

“…Triple-negative breast cancer (TNBC) is a biologically aggressive yet heterogeneous disease that disproportionately affects younger women and women of color…”
Get full text

31. A Phase I/II trial of ATI-2231 with Phase Ia in advanced soild tumor malignancies followed by Phase Ib/II in combination with capecitabine in patients with hormone receptor-positive (HR+) and HER2-negative metastatic breast cancer by Clifton, Katherine, Luo, Jingqin Rosy, Civitelli, Roberto, Geisler, Stefanie, Khan, Qamar, O'Sullivan, Ciara, Aggarwal, Ajay, Stewart, Sheila, Ma, Cynthia

Get full text

A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN) by Ademuyiwa, Foluso O., Northfelt, Donald W., O’Connor, Tracey, Levine, Ellis, Luo, Jingqin, Tao, Yu, Hoog, Jeremy, Laury, Marie L., Summa, Tracy, Hammerschmidt, Trish, Guo, Zhanfang, Frith, Ashley, Weilbaecher, Katherine, Opyrchal, Mateusz, Aft, Rebecca, Clifton, Katherine, Suresh, Rama, Bagegni, Nusayba, Hagemann, Ian S., Iglesia, Michael D., Ma, Cynthia X.

“…Patients with ER+/HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after chemotherapy with dual HER2 blockade than…”
Get full text

A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis by Krishnamurthy, Jairam, Luo, Jingqin, Suresh, Rama, Ademuyiwa, Foluso, Rigden, Caron, Rearden, Timothy, Clifton, Katherine, Weilbaecher, Katherine, Frith, Ashley, Roshal, Anna, Tandra, Pavan K., Cherian, Mathew, Summa, Tracy, Haas, Brittney, Thomas, Shana, Hernandez-Aya, Leonel, Bergqvist, Mattias, Peterson, Lindsey, Ma, Cynthia X.

“…Palbociclib 3-weeks-on/1-week-off, combined with hormonal therapy, is approved for hormone receptor positive (HR+)/HER2-negative (HER2−) advanced/metastatic…”
Get full text

Abstract PO1-20-08: Primary breast implant-associated squamous cell carcinoma with subsequent TEMPUS testing and failure of immunotherapy by Podany, Emily, Clifton, Katherine

“…Abstract Primary squamous cell carcinoma of the breast is a rare entity, and there are a limited number of cases in the literature describing squamous cell…”
Get full text

26566 Cutaneous reactions in clinical trials for oncologic drugs: An increasing need for dermatologic involvement by Yang, Jason J., So, Naomi, Maloney, Nolan, Arzeno, Julia, Clifton, Katherine, Bach, Daniel

Get full text

TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer by Layman, Rachel M., Jerzak, Katarzyna Joanna, Hilton, John Frederick, Clifton, Katherine, Alkuzweny, Baha, Mo, Gary, Valota, Olga, Perkins Smith, Julia, Anderson, Sibyl, Ma, Cynthia X.

“…TPS1121 Background: ARV-471, an oral PROTAC ER degrader, was well tolerated and showed evidence of clinical activity in a phase 1/2 study in heavily pretreated…”
Get full text

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases by Parkes, Amanda, Warneke, Carla L., Clifton, Katherine, Al‐Awadhi, Aydah, Oke, Oluchi, Pestana, Roberto Carmagnani, Alhalabi, Omar, Litton, Jennifer K., Hortobagyi, Gabriel N.

“…Background Patients with metastatic breast cancer with bone‐only metastases (BOM) are a unique patient population without consensus regarding high‐risk…”
Get full text

Abstract P5-11-03: Practice patterns and outcomes of post progression treatment after CDK 4/6 inhibitors by Clifton, Katherine Keaney, Raghavendra, Akshara Singareeka, Yi, Min, Litton, Jennifer, Tripathy, Debu, Karuturi, Meghan

“…Abstract Background: CDK 4/6 inhibitors have become frontline treatment for patients (pts) with advanced hormone receptor (HR) positive breast cancer. There is…”
Get full text

A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors by Hurvitz, Sara A., Hamilton, Erika P., Spira, Alexander I., Pohlmann, Paula R, Giordano, Antonio, Clifton, Katherine, Anderson, Barry Douglas, Dutta, Sujoy, Mangipudi, Umesh, Saini, Shikha, Palacino, James, Karunaratne, Tina, Greensmith, Dennise, Christensen, Olaf, Wilks, Sharon

“…TPS1114 Background: Targeted protein degradation (TPD) molecules have expanded the therapeutic options through their catalytic mechanism of action (MOA) and…”
Get full text

Differential genomic profiling of the progesterone receptor (PR) negative and estrogen receptor (ER) low metastatic breast cancer subtypes through circulating tumor DNA: A TNBC -like disease subtype? by Gerratana, Lorenzo, Davis, Andrew A., Foffano, Lorenzo, Reduzzi, Carolina, Podany, Emily L, Medford, Arielle J, Clifton, Katherine, Velimirovic, Marko, Putur, Annika, Munoz-Arcos, Laura Sofia, Pontolillo, Letizia, Tapiavala, Shaili, Molteni, Elisabetta, Nicolò, Eleonora, Gradishar, William John, Ma, Cynthia X., Andreopoulou, Eleni, Puglisi, Fabio, Bardia, Aditya, Cristofanilli, Massimo

“…1039 Background: ER positive/HER2 negative metastatic breast cancer (MBC) is typically regarded as a single entity, although significant clinical differences…”
Get full text

Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations by Clifton, Katherine, Gutierrez-Barrera, Angelica, Ma, Junsheng, Bassett, Roland, Litton, Jennifer, Kuerer, Henry, Moulder, Stacy, Albarracin, Constance, Hortobagyi, Gabriel, Arun, Banu

“…Purpose As triple-negative breast cancers are associated with earlier recurrences and poorer survival, optimal treatment of early-stage breast cancer is…”
Get full text

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer by Davis, Andrew A, Luo, Jingqin, Zheng, Tiantian, Dai, Chao, Dong, Xiaoxi, Tan, Lu, Suresh, Rama, Ademuyiwa, Foluso O, Rigden, Caron, Rearden, Timothy P, Clifton, Katherine, Weilbaecher, Katherine, Frith, Ashley, Tandra, Pavan K, Summa, Tracy, Haas, Brittney, Thomas, Shana, Hernandez-Aya, Leonel F, Peterson, Lindsay L, Wang, Xiaohong, Luo, Shujun J, Zhou, Kemin, Du, Pan, Jia, Shidong, King, Bonnie L, Krishnamurthy, Jairam, Ma, Cynthia X

“…Clinical biomarkers to identify patients unlikely to benefit from CDK4/6 inhibition (CDK4/6i) in combination with endocrine therapy (ET) are lacking. We…”
Get full text

Examining progression free survival (PFS), overall survival (OS), and toxicities of palbociclib in a geriatric population by Clifton, Katherine, Kimmel, Jaime, Litton, Jennifer Keating, Tripathy, Debu, Karuturi, Meghan Sri

“…Abstract only…”
Get full text

Abstract PO1-15-06: Serum thymidine kinase activity as a “real-time” clinical biomarker of tumor response to CDK4/6 inhibition in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer by Bagegni, Nusayba, Williams, Amy, Grigsby, Isabella, Bergqvist, Mattias, Clifton, Katherine, Ma, Cynthia

“…Abstract Background: CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) are standard first-line (1L) treatment for hormone receptor positive (HR+),…”
Get full text